TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05789303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15~Cycles 2-8: 56 mg/m2 on Days 1/8/15~Cycles 9+: 56 mg/m2 on Days 1/15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15~Cycles 2-8: 56 mg/m2 on Days 1/8/15~Cycles 9+: 56 mg/m2 on Days 1/15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 3 mg Day 1-21 of 28-day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 3 mg Day 1-21 of 28-day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycles 1-4: 40 mg Days 1/8/15/22~Cycles 5+: 20 mg Days 1/8/15/22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycles 1-4: 40 mg Days 1/8/15/22~Cycles 5+: 20 mg Days 1/8/15/22
Study: NCT05265624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early disclosure of genetic testing results
Description: Early disclosure group receives results of genetic testing at Month 1

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late disclosure of genetic testing results
Description: Late disclosure group receives results of genetic testing at Month 12
Study: NCT05340023

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: to realize proteomic analysis.
Study: NCT05135286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRIMOCHOL™ PF
Description: A single drop in each eye at a visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbachol PF
Description: A single drop in each eye at a visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: A single drop in each eye at a visit.
Study: NCT06138756

Intervention type: DEVICE
Intervention: Nerivio
Description: Neriio is a remote electrical neuromodulation (REN) device for the treatment of migraine
Study: NCT05155046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.
Study: NCT04950803

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome immunity formula
Description: Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 20 billion CFU daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Active placebo
Description: Active placebo contains active vitamin
Study: NCT04824144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
Study: NCT06279481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonpharmacological method
Description: Virtual reality
Study: NCT06452615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave
Description: The patients will receive 3000 to 6000 pulses every session by a radius of 15 mm probe (R15) at a frequency of 10 Hz, with energy gradually increasing from 1.4 to 1.5 bar
Study: NCT04748380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRC decision aid pamphlet
Description: A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Home Safety Pamphlet
Description: The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
Study: NCT03697343

Intervention type: RADIATION
Group type: OTHER
Intervention: Fractionated stereotactic radiotherapy
Description: Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm
Study: NCT05988411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal denervation using the Paradise renal denervation system - a dedicated Renal Denervation (RDN) catheter that delivers a circumferential ring of ablative ultrasound energy
Study: NCT04724811

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Description: Approaches used:~* Intrapelvic approach +/- iliac window~* Kocher-Langenbeck approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Description: Approaches used:~* Intrapelvic approach +/- iliac window~* Kocher-Langenbeck approach
Study: NCT06431919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg
Description: Simvastatin fixed dose of 20 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 3.125 mg
Description: Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 3.125 mg
Description: Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate
Study: NCT06161454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 40-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 40-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 40-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg
Study: NCT04909697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium
Description: 4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days
Study: NCT04244461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: The personalized normative feedback (PNF) focuses on behavioral norms, where participants see (1) how their perceptions compare to other same-gender veterans' actual drinking and (2) how their actual drinking compares to other same-gender veterans' actual drinking. The format of the intervention highlights typical days per week, drinks per occasion, and binge drinking as per traditional PNF interventions. PNF will also contain a video description of theories of normative influence (e.g., how individuals are affected by perceptions) and a description of the normative data sample. Participants also see enhanced PNF content that will focus on sharing with participants treatment information that the investigators obtained from a pilot sample.
Study: NCT06573086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 12-week resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 12-week resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 12-week resistance training
Study: NCT06572319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin(RC48) Plus Tratuzumab
Description: Disitamab Vedotin: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Tratuzumab: RP2D，ivgtt，D1, every 2 weeks for a treatment cycle.
Study: NCT05988411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation.
Study: NCT06574087

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: hrHPV test and cytology
Description: Perfomance of hrHPV test and cytology

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: hrHPV test and cytology
Description: Perfomance of hrHPV test and cytology
Study: NCT06259344

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fractioned Pain Science Education (FPSE)
Description: Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 2 sessions of 45 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Dosage Mode Pain Science Education (FDPSE)
Description: Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 6 sessions of 15 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial and Neck Exercises (ONE)
Description: Orofacial Exercises: Mandibular body-condylar cross-pressure chewing technique; Post-isometric relaxation stretches-laterotrusion and opening (10 times/session; 10 seconds).~Neck Motor Control Exercises: Bracing exercises (6 hierarchical levels - HL). Extreme range of motion exercises (stable spine). Cervical isometric exercises (5 HL) directly forward, obliquely, toward right and left, and directly backward (stable spine - elastic resistive bands). Functional training with elastic resistance and exercise balls on unstable surfaces (8 HJ). The progress in each exercise domain will happen when sustaining the contraction for 10 seconds, 10 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orofacial and Neck Exercises (ONE)
Description: Orofacial Exercises: Mandibular body-condylar cross-pressure chewing technique; Post-isometric relaxation stretches-laterotrusion and opening (10 times/session; 10 seconds).~Neck Motor Control Exercises: Bracing exercises (6 hierarchical levels - HL). Extreme range of motion exercises (stable spine). Cervical isometric exercises (5 HL) directly forward, obliquely, toward right and left, and directly backward (stable spine - elastic resistive bands). Functional training with elastic resistance and exercise balls on unstable surfaces (8 HJ). The progress in each exercise domain will happen when sustaining the contraction for 10 seconds, 10 times.
Study: NCT05720793

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FMT Capsule + SIMBA Capsule
Description: Participants in this arm will receive FMT capsules in addition to their usual treatment. participants will also be administered SIMBA sample collection capsules.
Study: NCT05600868

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A comprehensive third-generation intervention EMDR + dual attention
Description: This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with double attention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A comprehensive third-generation intervention EMDR + dual attention
Description: This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with double attention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A comprehensive third-generation intervention EMDR + fixed point
Description: This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with fixed point.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A comprehensive third-generation intervention EMDR + exposition
Description: This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with exposition.
Study: NCT06236152

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous sulfate
Description: Ferrous Sulphate was given once daily for 4 to 6 weeks to the patients instead of deltacortil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deltacortril
Description: Deltacortil 10mg was given orally once daily for 4 to 6 weeks
Study: NCT05755919

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epilepsy surgery
Description: Epilepsy surgery will be performed as a part of the clinical management of patients with drug-resistant epilepsy.
Study: NCT05214651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: novel double row
Description: The large - massive rotator cuff tears in in this group will be treated using a novel double row repairing techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture bridge double row
Description: The large - massive rotator cuff tears in in this group will be treated using a suture bridge double row repairing techniques.
Study: NCT06541730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-302168S
Description: Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DA-302168S
Description: Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
Study: NCT05092802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: 450mg bid po
Study: NCT06104592

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Comprehensive Ablative Bridging Irradiation (CABI)
Description: Participants will receive radiation therapy to all pretreatment lesions that are able to be feasibly and safely treated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Yascarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
Study: NCT06267118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline Solution, 1 Ml
Description: Dilute 0.3 ml hypertonic saline with 3 ml normal saline for nebulization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: dilute 0.3 ml adrenaline with 3 ml normal saline for nebulization
Study: NCT04460521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: In addition to splinting, both groups will receive an oral tablet to take daily for 8 weeks. Participants assigned to the experimental group will receive oral NAC (500 mg PO daily for eight weeks; based on recommended daily dose for use as an antioxidant and dosing in previous human clinical trials and animal studies), and those assigned to the control group will be given a similar looking placebo with identical instructions. Tablets will be provided in a blister pack to assist with compliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Splint
Description: Participants in both arms will be given a standard prescription for a prefabricated night splint which keeps the wrist in a neutral position and instructed on proper use and the importance of consistent use. To limit splint variability, we will ensure that splint prescriptions are written such that a MedSpec Wrist Lacer II splint is obtained from the patient's pharmacy. This is the most commonly available brand locally and meets the criteria for wrist, metacarpophalangeal, and interphalangeal joint positioning. They will be advised to wear the splint consistently during sleeping hours on their affected wrist for eight weeks, as is the standard of practice.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wrist Splint
Description: Participants in both arms will be given a standard prescription for a prefabricated night splint which keeps the wrist in a neutral position and instructed on proper use and the importance of consistent use. To limit splint variability, we will ensure that splint prescriptions are written such that a MedSpec Wrist Lacer II splint is obtained from the patient's pharmacy. This is the most commonly available brand locally and meets the criteria for wrist, metacarpophalangeal, and interphalangeal joint positioning. They will be advised to wear the splint consistently during sleeping hours on their affected wrist for eight weeks, as is the standard of practice.
Study: NCT06115759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-REX Twente precautions
Description: The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual (restrictive) sternal precautions
Description: The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
Study: NCT03948074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Medicinal Cannabis Oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Medicinal Cannabis Oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Medicinal Cannabis Oil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Description: Medicinal Cannabis Oil
Study: NCT05774067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: patient received normal saline 4ml/kg/hr with deflation of tourniquet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: patient received noradrenaline infusion at rate 0.1 mcg/kg/min. with deflation of tourniquet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glypressin
Description: patient receive glypressin infusion at rate 2 mcg/kg/hr.
Study: NCT05973539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Eucaloric diet enriched in either carbohydrates or fat (both contributing to 65% total energy intake)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Eucaloric diet enriched in either carbohydrates or fat (both contributing to 65% total energy intake)
Study: NCT04871360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline supplement
Description: The intervention will consist of oral supplementation of six grams of pure l-citrulline for eight weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carboxymethyl cellulose supplement
Description: The intervention will consist of oral carboxymethyl cellulose supplementation as a placebo.
Study: NCT06254859

Intervention type: PROCEDURE
Intervention: Traditional thyroid surgery.
Description: The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.

Intervention type: PROCEDURE
Intervention: Traditional thyroid surgery.
Description: The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.

Intervention type: PROCEDURE
Intervention: Traditional thyroid surgery.
Description: The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.

Intervention type: PROCEDURE
Intervention: Traditional thyroid surgery.
Description: The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.
Study: NCT06003673

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: The enrolled patients undergo 2 cycles of neoadjuvant therapy, with each cycle consisting of treatment every 3 weeks. On the first day of the first treatment cycle, conventional transarterial chemoembolization (TACE) is performed, and concomitant intravenous infusion of tislelizumab at a dose of 200mg is given, followed by oral administration of lenvatinib at a dose of 8/12mg once daily. On the first day of the second cycle, tislelizumab is again administered intravenously at a dose of 200mg, TACE is not repeated, and lenvatinib treatment is continued. Within 2-4 weeks after the completion of neoadjuvant therapy, the investigator evaluates the tumor's suitability for surgical resection based on a comprehensive assessment of imaging results. Subsequently, eligible patients undergo tumor resection surgery, followed by follow-up for survival and safety monitoring.